鄭文婷，研究員，博士研究生導(dǎo)師，研究方向聚焦于免疫細(xì)胞行為的工程化改造及腫瘤治療應(yīng)用，重點(diǎn)圍繞“工程化方法賦能免疫細(xì)胞用于腫瘤治療”開展研究。運(yùn)用小鼠和人免疫細(xì)胞治療模型、CRISPR-Cas9篩選技術(shù)等探索賦能免疫細(xì)胞的新靶點(diǎn)和策略，應(yīng)用工程化的研究手段改造細(xì)胞療法的功能元件，利用新型生物材料靶向性改造疾病微環(huán)境，優(yōu)化免疫細(xì)胞功能，改善腫瘤治療。 院校引進(jìn)人才，2021年加入院校，曾在美國(guó)St. Jude Children’s Research Hospital從事博士后研究。

長(zhǎng)期從事免疫細(xì)胞治療腫瘤的研究，針對(duì)現(xiàn)行的細(xì)胞療法易復(fù)發(fā)、患者生存率低等臨床問題，未來(lái)將在“免疫細(xì)胞行為的工程化改造及腫瘤治療應(yīng)用”領(lǐng)域，充分利用多學(xué)科交叉的優(yōu)勢(shì)，重點(diǎn)圍繞“工程化方法賦能T細(xì)胞用于腫瘤治療”開展研究，以期解決腫瘤精準(zhǔn)治療和難治復(fù)發(fā)的難題。承擔(dān)國(guó)自然青年項(xiàng)目，以第一/通訊作者在 J Immunother Cancer、Blood、Leukemia、Adv Funct Mater、JACS 等刊物上發(fā)表十余篇論文，總引1700余次，獲得國(guó)際專利2項(xiàng)。

午夜92福利1000,午夜92福利1000,久久国产亚洲高清观看5388,美女不拍网站免费观看,欧美***天天久久综合精品,中文字幕日韩系列中文字幕,综合久久国产九一剧情麻豆,丰满人妻在线免费视频,奶子大逼又嫩操起来真爽

1.Wei Liu#, Wei Liu#, Hesong Zou#, Lianting Chen#, Wenyang Huang, Rui lv, Yan Xu, Huimin Liu, Yin Shi, Kefei Wang, Yi Wang, Wenjie Xiong, Shuhui Deng, Shuhua Yi, Weiwei Sui, Guangxin Peng, Yueshen Ma, Huijun Wang, Lulu Lv, Jianxiang Wang, Jun Wei*, Lugui Qiu*, Wenting Zheng*, Dehui Zou*. Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma. Journal for ImmunoTherapy of Cancer, 2024 Apr 16;12(4): e008857.

2.Xiaoyan Zhang#, Kefei Wang#, Zhiyuan Gao, Zelin Wu, Wei Liu, Jisen Li, Heqi Gao, Jun Wei, Dan Ding*, Wenting Zheng*. An Aggregation-Induced Emission Molecule-Assembled Nanovaccine with Self-Adjuvanted Function for Cancer Immunotherapy, Advanced Functional Materials, 2023, 33(51): 2302118.

3. Yiming Zhang#, Zhiwen Hu, Xinxin Li, Yinghao Ding, Zhenghao Zhang, Xiangyang Zhang, Wenting Zheng*, Zhimou Yang*. Amino acid sequence determines the adjuvant potency of a D-Tetra-Peptide hydrogel, Biomaterials Science, 2022 Jun 14;10(12):3092-3098.

4. Wenting Zheng#, Jun Wei, Caitlin Zebley, Lindsay L Jones, Yogesh Dhungana, Yong-Dong Wang, Jayadev Mavuluri, Lingyun Long, Yiping Fan, Benjamin Youngblood, Hongbo Chi, Terrence L Geiger*. Regnase-1 suppresses TCF-1+ precursor exhausted T cell formation to limit CAR T cell responses against ALL, Blood, 2021, 138(2): 122-135.

5.Wenting Zheng#, Carol E. O'Hear, Rajshekhar Alli, Jacob H. Basham, Hossam A. Abdelsamed, Lance E. Palmer, Lindsay L. Jones, Ben Youngblood, Terrence L. Geiger*. PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells, Leukemia, 2018, 32: 1157-1167.